Novel Adamantanyl-Based Thiadiazolyl Pyrazoles Targeting EGFR in Triple-Negative Breast Cancer

[Image: see text] The epidermal growth factor receptor (EGFR) is a validated therapeutic target for triple-negative breast cancer (TNBC). In the present study, we synthesize novel adamantanyl-based thiadiazolyl pyrazoles by introducing the adamantane ring to thiazolopyrazoline. On the basis of loss...

Descripción completa

Detalles Bibliográficos
Autores principales: Sebastian, Anusha, Pandey, Vijay, Mohan, Chakrabhavi Dhananjaya, Chia, Yi Ting, Rangappa, Shobith, Mathai, Jessin, Baburajeev, C. P., Paricharak, Shardul, Mervin, Lewis H., Bulusu, Krishna C., Fuchs, Julian E., Bender, Andreas, Yamada, Shuhei, Basappa, Lobie, Peter E., Rangappa, Kanchugarakoppal S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2016
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6044684/
https://www.ncbi.nlm.nih.gov/pubmed/30023509
http://dx.doi.org/10.1021/acsomega.6b00251

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6044684/
https://www.ncbi.nlm.nih.gov/pubmed/30023509
http://dx.doi.org/10.1021/acsomega.6b00251

Ejemplares similares